Skip to main content

Table 4 Univariate analyses and multivariate analyses for progression-free survival in patients with endometrial carcinoma about clinicopathological features and mesothelin, CA125 expressions

From: Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis

Variables   Univariate analysis Multivariate analysis for mesothelin expression Multivariate analysis for co-expression of mesothelin and CA125
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age ≥ 60 vs. <  60 2.18 (1.50–3.23) < 0.01 1.79 (1.19–2.72) < 0.01 1.79 (1.19–2.73) < 0.01
Histological type Grade 2 endometrioid carcinoma vs. Grade 1 endometrioid carcinoma 3.37 (1.95–5.96) < 0.01 2.01 (1.12–3.67) 0.019 2.02 (1.12–3.69) 0.018
  Grade 3 endometrioid carcinoma vs. Grade 1 endometrioid carcinoma 5.17 (2.88–9.36) < 0.01 2.83 (1.49–5.42) < 0.01 2.84 (1.50–5.45) < 0.01
  Other carcinomas vs. Grade 1 endometrioid carcinoma 8.92 (4.41–12.6) < 0.01 2.48 (1.34–4.70) < 0.01 2.49 (1.35–4.72) < 0.01
FIGO stage III. IV vs. I. II 7.82 (5.42–11.4) < 0.01 2.07 (1.08–3.94) 0.028 2.07 (1.07–3.93) 0.029
Depth of myometrial invasion ≥1/2 vs. < 1/2 3.84 (2.66–5.60) < 0.01 1.59 (0.99–2.58) 0.054 1.57 (0.97–2.55) 0.061
Lymphovascular invasion Yes vs. No 3.84 (2.62–5.75) < 0.01 1.94 (1.16–3.25) 0.01 1.94 (1.17–3.25) 0.01
Cervical invasion Yes vs. No 2.23 (1.50–3.25) < 0.01 1.44 (0.92–2.24) 0.10 1.45 (0.92–2.45) 0.10
Ovarian metastasis Yes vs. No 7.48 (4.68–11.5) < 0.01 1.21 (0.67–2.13) 0.51 1.21 (0.67–2.14) 0.50
Lymph node metastasis Yes vs. No 5.64 (3.68–8.58) < 0.01 1.26 (0.70–2.31) 0.44 1.25 (0.69–2.30) 0.45
  Yes vs. Unevaluated 1.94 (1.20–3.14) < 0.01 1.27 (0.71–2.31) 0.41 1.27 (0.70–2.31) 0.41
  Unevaluated vs. No 2.91 (1.84–4.51) < 0.01 0.96 (0.57–1.68) 0.96 0.98 (0.57–1.67) 0.96
Distant metastasis Yes vs. No 12.5 (8.14–18.9) < 0.01 5.89 (3.11–11.1) < 0.01 5.87 (3.10–11.1) < 0.01
Peritoneal cytology Positive vs. Negative 4.42 (3.04–6.38) < 0.01 1.59 (0.98–2.58) 0.058 1.59 (0.97–2.57) 0.06
Adjuvant therapy Yes vs. No 2.55 (1.71–3.89) < 0.01 0.45 (0.26–0.78) < 0.01 0.45 (0.26–0.78) < 0.01
Mesothelin expression Yes vs. No 2.74 (1.91–3.94) < 0.01 2.14 (1.45–3.16) < 0.01    
CA125 expression Yes vs. No 1.01 (0.68–1.56) 0.92       
Co-expression of mesothelin and CA125 Yes vs. No 2.86 (2.00–4.12) < 0.01     2.19 (1.49–3.23) < 0.01
  1. CI confidence interval, HR hazard ratio, CA125 cancer antigen 125, other carcinomas carcinomas including serous carcinoma, clear cell carcinoma, carcinosarcoma, and mixed carcinoma, FIGO International Federation of Obstetrics and Gynecology